Policy & Regulation
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administ...
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royal...
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
3 September 2026 - Sensorion (Euronext Growth Paris:ALSEN), a clinical-stage biotechnology company that specialises in hearing loss therapies, said on Thursday that it has received authorisation from ...
Foventa makes key CMO and CFO appointments
3 September 2026 - Foventa Therapeutics, a biotechnology company focused on novel therapies for retinal vascular diseases, announced on Wednesday that it has further strengthened its management team w...
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
3 September 2026 - Biopharmaceutical company Akeso Inc (HKEX:9926) announced on Wednesday that a pre-specified interim analysis in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data ...
Teva reports positive Phase 2a data for TEV '408 in celiac disease
2 September 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Wednesday reported positive top-line results from an ongoing Phase 2a study of TEV &...